Literature DB >> 12527806

Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).

Zhe-Sheng Chen1, Elizabeth Hopper-Borge, Martin G Belinsky, Irina Shchaveleva, Elena Kotova, Gary D Kruh.   

Abstract

Human multidrug resistance protein 7 (MRP7, ABCC10) is a recently described member of the C family of ATP binding cassette proteins (Cancer Lett 162:181-191, 2001). However, neither its biochemical activity nor physiological functions have been determined. Here we report the results of investigations of the in vitro transport properties of MRP7 using membrane vesicles prepared from human embryonic kidney 293 cells transfected with MRP7 expression vector. It is shown that expression of MRP7 is specifically associated with the MgATP-dependent transport of 17beta-estradiol-(17-beta-D-glucuronide) (E(2)17betaG). E(2)17betaG transport was saturable, with K(m) and V(max) values of 57.8 +/- 15 microM and 53.1 +/- 20 pmol/mg/min. By contrast, with E(2)17betaG, only modest enhancement of LTC(4) transport was observed and transport of several other established substrates of MRP family transporters was not detectable to any extent. In accord with the notion that MRP7 has a bipartite substrate binding pocket composed of sites for anionic and lipophilic moieties, transport of E(2)17betaG was susceptible to competitive inhibition by both amphiphiles, such as leukotriene C(4) (K(i(app)), 1.5 microM), glycolithocholate 3-sulfate (K(i(app)), 34.2 microM) and MK571 (K(i(app)), 28.5 microM), and lipophilic agents such as cyclosporine A (K(i(app)), 14.4 microM). Of the inhibitors tested, LTC(4) was the most potent, in agreement with the possibility that it is a substrate of the pump. The determination that MRP7 has the facility for mediating the transport of conjugates such as E(2)17betaG indicates that it is a lipophilic anion transporter involved in phase III (cellular extrusion) of detoxification.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527806     DOI: 10.1124/mol.63.2.351

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  54 in total

Review 1.  Pharmacogenetics and pharmacoepigenetics of gemcitabine.

Authors:  M Candelaria; E de la Cruz-Hernández; E Pérez-Cárdenas; C Trejo-Becerril; O Gutiérrez-Hernández; A Dueñas-González
Journal:  Med Oncol       Date:  2009-11-10       Impact factor: 3.064

Review 2.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

3.  Identification of a human ABCC10 orthologue in Catharanthus roseus reveals a U12-type intron determinant for the N-terminal domain feature.

Authors:  Taissir El-Guizani; Clotilde Guibert; Saida Triki; Benoit St-Pierre; Eric Ducos
Journal:  J Genet       Date:  2014-04       Impact factor: 1.166

4.  Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.

Authors:  Elizabeth A Hopper-Borge; Timothy Churchill; Chelsy Paulose; Emmanuelle Nicolas; Joely D Jacobs; Olivia Ngo; Yehong Kuang; Alex Grinberg; Heiner Westphal; Zhe-Sheng Chen; Andres J Klein-Szanto; Martin G Belinsky; Gary D Kruh
Journal:  Cancer Res       Date:  2011-05-15       Impact factor: 12.701

5.  Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent.

Authors:  Vaibhav Mundra; Yan Lu; Michael Danquah; Wei Li; Duane D Miller; Ram I Mahato
Journal:  Pharm Res       Date:  2012-09-28       Impact factor: 4.200

6.  Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.

Authors:  Ning Ji; Yuqi Yang; Chao-Yun Cai; Zi-Ning Lei; Jing-Quan Wang; Pranav Gupta; Suneet Shukla; Suresh V Ambudkar; Dexin Kong; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2018-10-10       Impact factor: 8.679

7.  Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma.

Authors:  Ruinan Yang; Goutam Mondal; Rachel A Ness; Kinsie Arnst; Vaibhav Mundra; Duane D Miller; Wei Li; Ram I Mahato
Journal:  J Control Release       Date:  2017-01-24       Impact factor: 9.776

8.  Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study.

Authors:  Rishil J Kathawala; Kamlesh Sodani; Kang Chen; Atish Patel; Alaa H Abuznait; Nagaraju Anreddy; Yue-Li Sun; Amal Kaddoumi; Charles R Ashby; Zhe-Sheng Chen
Journal:  Mol Cancer Ther       Date:  2014-01-15       Impact factor: 6.261

9.  Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.

Authors:  Yi-Jun Wang; Rishil J Kathawala; Yun-Kai Zhang; Atish Patel; Priyank Kumar; Suneet Shukla; King Leung Fung; Suresh V Ambudkar; Tanaji T Talele; Zhe-Sheng Chen
Journal:  Biochem Pharmacol       Date:  2014-06-14       Impact factor: 5.858

10.  ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.

Authors:  De-Shen Wang; Atish Patel; Hong-May Sim; Yun-Kai Zhang; Yi-Jun Wang; Rishil J Kathawala; Hui Zhang; Tanaji T Talele; Suresh V Ambudkar; Rui-Hua Xu; Zhe-Sheng Chen
Journal:  J Cell Biochem       Date:  2014-08       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.